<DOC>
	<DOCNO>NCT01332487</DOCNO>
	<brief_summary>This retrospective study aim assess impact early v delay 5-alpha-reductase inhibitor ( 5ARI ) therapy patient BPH alpha-blocker ( AB ) therapy risk acute urinary retention ( AUR ) , prostate-related surgery , emergency surgery ( define prostate surgery occur within 30 day AUR ) . The MarketScan database utilized study ( 2000-2008 ) .</brief_summary>
	<brief_title>Evaluating Impact Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment Risk Emergent Surgery Men With Benign Prostatic Hyperplasia</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>5-alpha Reductase Inhibitors</mesh_term>
	<criteria>Male age 50 year older diagnostic claim BPH prescription claim AB 5ARI observation period ( 5ARI must occur within 6month window AB ) . continuously eligible 6 month prior 12 month index prescription date prostate bladder cancer study period prostaterelated surgical procedure within 5 month index prescription date prescription claim finasteride 1 mg male pattern baldness study period 5ARI therapy prior initiation AB therapy</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>5-alpha-reductase inhibitor</keyword>
	<keyword>prostate surgery</keyword>
	<keyword>alpha-blocker</keyword>
	<keyword>enlarge prostate</keyword>
	<keyword>acute urinary retention</keyword>
	<keyword>Benign prostatic hyperplasia</keyword>
</DOC>